Efranat Pharma

Anticancer Immunotherapy Treatment

Health Tech & Life Sciences
Non Active, Nov 2018 ceased to operate
Mature Rehovot, Israel Founded 2009
LinkedIn
Last updated 2026-06-18
Total raised
$4.5M
Last: 2014-11
Stage
Mature
Founded
2009
Headcount
30
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences

About

Efranat Pharma is developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. The technology is based on the concept of engaging the bodys own immune system and harnessing it against cancer. Efranat has succeeded in engineering a natural vitamin D binding protein into a potent immune modulator to fight cancer and chronic viral diseases. The companys primary product, EF-022, is an immunomodulator that activates macrophages, a group of white blood cells that play a key role in the immune systems defense against cancer. The product is manufactured and processed under GMP in a procedure that mimics the natural process in the body. A test involving 14 dogs with cancer that were treated with EF-022 showed promising results. Efranat is currently conducting a phase 1 clinical trial in human cancer patients with advanced solid tumors at the Sheba Medical Center.

Funding history · 1 round · $4.5M total

Q&A

What is Efranat Pharma's primary focus?
Efranat Pharma is developing an anticancer immunotherapy treatment based on a natural plasma protein molecule, aiming to engage the body's own immune system against cancer.
What is the status of Efranat Pharma?
Efranat Pharma is currently inactive, having ceased operations in November 2018.
When was Efranat Pharma founded?
Efranat Pharma was founded in December 2009.
What is Efranat Pharma's main product?
Efranat Pharma's primary product is EF-022, an immunomodulator designed to activate macrophages to fight cancer and chronic viral diseases.
What was the total amount of funding raised by Efranat Pharma?
Efranat Pharma raised a total of $4,500,000.
When did Efranat Pharma complete its last funding round and who were the investors?
Efranat Pharma completed its last funding round in November 2014, with investors including Yuval Yanai and Isaac-Friedman.
How many employees did Efranat Pharma have?
Efranat Pharma had an employee count in the 11-50 range.
Where is Efranat Pharma headquartered?
Efranat Pharma is headquartered in Rehovot, Center District, Israel.

Team · 2

Founder · Co-Founder
LinkedIn ↗
Founder · Co-Founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2C

Highlights

1 Patents

Tags

oncologytherapeuticsbiopharmaceuticalimmunologycancerproteinspatientspharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/2679683

Identifiers & details

Founded2009-12
Employees (exact)30
Status reasonNon Active, Nov 2018 ceased to operate